Aviragen Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Aviragen Therapeutics's estimated annual revenue is currently $3.1M per year.
- Aviragen Therapeutics's estimated revenue per employee is $81,600
Employee Data
- Aviragen Therapeutics has 38 Employees.
- Aviragen Therapeutics grew their employee count by -3% last year.
Aviragen Therapeutics's People
| Name | Title | Email/Phone |
|---|
Aviragen Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1M | 16 | -11% | N/A | N/A |
#2 | $6.4M | 70 | 63% | N/A | N/A |
#3 | $3.1M | 38 | -3% | N/A | N/A |
#4 | $3.8M | 46 | N/A | N/A | N/A |
#5 | $3.7M | 45 | 2% | N/A | N/A |
#6 | $2.5M | 31 | 11% | N/A | N/A |
#7 | $2.9M | 39 | -19% | $33.4M | N/A |
#8 | $22.2M | 198 | -2% | N/A | N/A |
#9 | $0.2M | 4 | N/A | N/A | N/A |
#10 | $3.3M | 41 | 8% | N/A | N/A |
What Is Aviragen Therapeutics?
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplatovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papillomavirus types 6 & 11.
keywords:N/A
N/A
Total Funding
38
Number of Employees
$3.1M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Alpharetta
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.6M | 38 | -5% | N/A |
#2 | $4.4M | 38 | -10% | N/A |
#3 | $10.7M | 38 | 0% | N/A |
#4 | $10.6M | 38 | 3% | N/A |
#5 | $7.4M | 38 | 3% | N/A |